Want to see ZNTL full AI Analyst Report?

Zentalis Pharmaceuticals (ZNTL) Price & Analysis

416 Followers

ZNTL Stock Chart & Stats

$3.88

-$0.17(-5.69%)

At close: Jan 08 4:00 PM EST

$3.88

-$0.17(-5.69%)

Day’s Range― - ―

52-Week Range$1.21 - $6.95

Previous CloseN/A

Volume750.15K

Average Volume (3M)1.07M

Market Cap

$262.24M

Enterprise Value$209.01

Total Cash (Recent Filing)$174.61M

Total Debt (Recent Filing)$37.69M

Price to Earnings (P/E)―

Beta3.33

Next Earnings

Nov 11, 2026

EPS Estimate

-0.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.46

Shares Outstanding94,671,910

10 Day Avg. Volume1,495,503

30 Day Avg. Volume1,074,589

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)0.45

Price to Sales (P/S)0.00

P/FCF Ratio-0.77

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$8.17

Price Target Upside110.48% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)-2.13

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Late-stage Oncology PipelineProgress toward registration-intended trials and a confirmatory Phase 3 study provides a clearer development path for azenosertib. FDA feedback without objections to the proposed regimen or population reduces a key execution hurdle and supports potential future commercialization.

Funding RunwayA cash runway extending into late 2027 gives Zentalis time to advance important clinical programs without an immediately pressing financing requirement. That financial time horizon can support trial execution, regulatory work, and value creation from pipeline milestones.

Relatively Low LeverageModest debt relative to equity limits the burden of interest and mandatory repayment obligations compared with more highly leveraged biotechnology companies. This provides some balance-sheet flexibility while Zentalis invests in clinical development and works toward potential commercialization.

Bears Say

Unestablished Product RevenueZentalis remains dependent on clinical development rather than an established commercial product franchise, so operating performance is not yet supported by recurring customer revenue. Until approval and launch occur, future economics depend heavily on successful trials and regulatory progress.

Persistent Cash BurnSustained negative operating and free cash flow means the business is consuming capital rather than funding development internally. The renewed increase in TTM burn could shorten financial flexibility over time and make additional external funding necessary if spending remains elevated.

Shrinking Equity BaseThe substantial reduction in the equity base signals cumulative value erosion while the company remains unprofitable. Continued losses can weaken financial resilience and increase reliance on future capital raises, making long-term ownership economics more dependent on financing outcomes.

Zentalis Pharmaceuticals News

Zentalis initiated with an Outperform at William Blair

William Blair initiated coverage of Zentalis (ZNTL) with an Outperform rating. The firm cites the potential of the...

17d ago

ZNTL

Zentalis announecs common stock offering, no amount given

Zentalis (ZNTL) Pharmaceuticals announced the commencement of a proposed underwritten public offering of shares of its common stock...

2M ago

ZNTL

Zentalis 23M share Spot Secondary priced at $3.50

TD Cowen, Guggenheim and Oppenheimer acted as joint book running managers for the offering. Published first on TheFly...

2M ago

ZNTL

Zentalis Pharmaceuticals Announces Major Common Stock Offering

Zentalis Pharmaceuticals ( ($ZNTL) ) has issued an announcement. On August 13, 2026, Zentalis Pharmaceuticals entered into an...

2M ago

ZNTL

Zentalis price target raised to $5 from $4 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Zentalis (ZNTL) to $5 from $4 and keeps an Equal...

2M ago

ZNTL

Regulatory Clarity and Trial Progress Support Azenosertib Outlook; Buy Rating Reiterated with Unchanged $10 Price Target

Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals and keeping the price...

2M ago

ZNTL

Zentalis reports Q2 EPS (59c), consensus (48c)

“We have achieved important milestones on the continued advancement of azenosertib in our registration-intended DENALI Phase 2 and...

2M ago

ZNTL

Zentalis Highlights Q2 Results and Azenosertib Progress

An announcement from Zentalis Pharmaceuticals ( ($ZNTL) ) is now available. On August 6, 2026, Zentalis Pharmaceuticals reported...

2M ago

ZNTL

Zentalis initiated with a Buy at Rodman & Renshaw

Rodman & Renshaw initiated coverage of Zentalis (ZNTL) with a Buy rating and $11 price target The firm...

2M ago

ZNTL

Zentalis initiated with an Outperform at Mizuho

Mizuho analyst Graig Suvannavejh initiated coverage of Zentalis (ZNTL) with an Outperform rating and $8 price target The...

3M ago

ZNTL

Zentalis Shareholders Back Directors, Auditors and Executive Pay

Zentalis Pharmaceuticals ( ($ZNTL) ) has shared an update. On June 16, 2026, Zentalis Pharmaceuticals, Inc. held its...

4M ago

ZNTL

Zentalis assumed with an Outperform at Oppenheimer

Oppenheimer assumed coverage of Zentalis (ZNTL) with an Outperform rating and $9 price target The company is entering...

4M ago

ZNTL

Zentalis Pharmaceuticals Expands Board, Appoints New Director

The latest update is out from Zentalis Pharmaceuticals ( ($ZNTL) ). Effective May 22, 2026, Zentalis Pharmaceuticals expanded...

4M ago

ZNTL

Analyst Reiterates Buy on Zentalis as New MUIR Data Bolster Azenosertib Outlook; $10 Price Target Unchanged

In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Zentalis Pharmaceuticals,...

4M ago

ZNTL

ZNTL FAQ

What was Zentalis Pharmaceuticals’s price range in the past 12 months?

Zentalis Pharmaceuticals lowest stock price was $1.21 and its highest was $6.95 in the past 12 months.

What is Zentalis Pharmaceuticals’s market cap?

Zentalis Pharmaceuticals’s market cap is $262.24M.

When is Zentalis Pharmaceuticals’s upcoming earnings report date?

Zentalis Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 40 days.

How were Zentalis Pharmaceuticals’s earnings last quarter?

Zentalis Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.49 by -$0.1.

Is Zentalis Pharmaceuticals overvalued?

According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zentalis Pharmaceuticals pay dividends?

Zentalis Pharmaceuticals does not currently pay dividends.

What is Zentalis Pharmaceuticals’s EPS estimate?

Zentalis Pharmaceuticals’s EPS estimate is -0.57.

How many shares outstanding does Zentalis Pharmaceuticals have?

Zentalis Pharmaceuticals has 94,671,910 shares outstanding.

What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?

Zentalis Pharmaceuticals reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.49. Following the earnings report the stock price went down -15.6%.

Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?

Currently, no hedge funds are holding shares in ZNTL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Zentalis Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-38.78%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals (ZNTL) Earnings & Revenues

Historic Earnings Reports

ZNTL Stock 12 Month Forecast

Average Price Target

$8.17

▲(110.48% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","9":"$9","12":"$12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.166666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3,6,9,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.605,3.250769230769231,3.8965384615384613,4.542307692307692,5.188076923076923,5.833846153846154,6.479615384615384,7.125384615384615,7.771153846153846,8.416923076923077,9.062692307692307,9.708461538461538,10.35423076923077,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.605,3.032820512820513,3.4606410256410256,3.888461538461538,4.316282051282051,4.744102564102564,5.171923076923076,5.599743589743589,6.027564102564102,6.455384615384615,6.883205128205127,7.3110256410256405,7.738846153846152,{"y":8.166666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.605,2.789230769230769,2.9734615384615384,3.1576923076923076,3.3419230769230768,3.526153846153846,3.7103846153846156,3.894615384615385,4.078846153846154,4.263076923076923,4.447307692307692,4.631538461538462,4.815769230769231,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.57,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.355,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.74,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.605,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >